



OPEN ACCESS

EDITED AND REVIEWED BY
John M. Seubert,
University of Alberta, Canada

*CORRESPONDENCE
Haiyang Zhang,
✉ zhangocan666@sina.com

RECEIVED 26 March 2025
ACCEPTED 29 May 2025
PUBLISHED 12 June 2025

CITATION

Li S, Zhang L and Zhang H (2025) Corrigendum:
A telomere-related signature for predicting
prognosis and assessing immune
microenvironment in osteosarcoma.
Front. Pharmacol. 16:1600217.
doi: 10.3389/fphar.2025.1600217

COPYRIGHT

© 2025 Li, Zhang and Zhang. This is an open-
access article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma

Shihao Li¹, Lina Zhang¹ and Haiyang Zhang^{2*}

¹Department of Orthopedics, Zibo Central Hospital West Campus, Zibo, China, ²Department of Hand and Foot Surgery, Zibo Central Hospital, Zibo, China

KEYWORDS

osteosarcoma, telomere-related signature, prognosis, immune microenvironment, drug sensitivity, MAP7

A Corrigendum on

A telomere-related signature for predicting prognosis and assessing immune microenvironment in osteosarcoma

by Li S, Zhang L and Zhang H (2025). *Front. Pharmacol.* 15:1532610. doi: 10.3389/fphar.2024.1532610

In the published article, there was an error in [Figure 9](#) as published. The micrograph scale was omitted in [Figure 9E](#), meaning that both the scale bar and duplication needed correction. As such, we magnified the ruler to make the Transwell analysis images clearer. The corrected [Figure 9](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 9
Overexpression of MAP7 might inhibit tumor proliferation, migration, and the invasion of osteosarcoma cells. **(A)** Expression of MAP7 in hFOB1.19, HOS, U-2OS, and SAOS-2 cells. Overexpression efficiency of MAP7 was evaluated by qRT-PCR **(B)** and Western blotting **(C)**. **(D)** Cell proliferation was detected using CCK-8 assays. **(E)** The ability of cell migration and invasion was detected using the Transwell assay. * means $P < 0.05$, ** $P < 0.01$, *** means $P < 0.001$, and **** means $P < 0.0001$.